Safety and Efficacy of Bexagliflozin as Monotherapy in Patients With Type 2 Diabetes

Completed · Phase 3 · Has a placebo group

Conditions studied: Type 2 Diabetes Mellitus

In brief

The purpose of this study is to investigate the effect of bexagliflozin in lowering hemoglobin A1c (HbA1c) levels in patients with type 2 diabetes mellitus (T2DM).

Key facts

Study ID

NCT02715258

Run by

Theracos

People needed

210

Starts

2016-03-01

Expected to finish

2017-04-01

Last updated by the study team

2021-06-28

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Research Site — Canoga Park, California, United States
• Research Site — Chino, California, United States
• Research Site — Huntington Park, California, United States
• Research Site — Los Angeles, California, United States
• Research Site — San Diego, California, United States
• Research Site — Fort Lauderdale, Florida, United States
• Research Site — Hialeah, Florida, United States
• Research Site — Miami Lakes, Florida, United States
• Research Site — Orlando, Florida, United States
• Research Site — Port Orange, Florida, United States
• Research Site — Trenton, New Jersey, United States
• Research Site — Calabash, North Carolina, United States
• Research Site — Morehead City, North Carolina, United States
• Research Site — Munroe Falls, Ohio, United States
• Research Site — Portland, Oregon, United States
• Research Site — North Myrtle Beach, South Carolina, United States
• Research Site — DeSoto, Texas, United States
• Research Site — Fort Worth, Texas, United States
• Research Site — Vancouver, British Columbia, Canada
• Research Site — Newmarket, Ontario, Canada
• Research Site 2 — Toronto, Ontario, Canada
• Research Site 1 — Toronto, Ontario, Canada
• Research Site — Pointe-Claire, Quebec, Canada

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.